Overview

Preoperative Therapy in Patients With Stages IB, II, IIIA, and Selected IIIB Patients With Non-Small Cell Lung Cancer

Status:
Completed
Trial end date:
2008-12-01
Target enrollment:
Participant gender:
Summary
This trial is designed to study the role of docetaxel/gemcitabine, an active and relatively non-toxic combination in advanced NSCLC. This study will help to better define optimal preoperative regimens for patients with resectable NSCLC. Since both of these drugs are potent radio-sensitizers, the concurrent use with radiation therapy at these weekly doses may produce not only radio-sensitization, but also considerable antitumor efficacy.
Phase:
Phase 2
Details
Lead Sponsor:
SCRI Development Innovations, LLC
Collaborators:
Aventis Pharmaceuticals
Eli Lilly and Company
Treatments:
Carboplatin
Docetaxel
Gemcitabine